BERLIN, May 10 (Reuters) - Germany has no findings that
would change its recommendation on the use of AstraZeneca's
COVID-19 vaccine following reports of a rare
nerve-degenerating disorder in people who received the shot,
health minister Jens Spahn said on Monday.
Europe's medicines regulator is analysing data provided by
AstraZeneca on cases of Guillain-Barre syndrome (GBS), raising
fresh questions about potential side-effects of the vaccine.
(Reporting by Caroline Copley, editing by Thomas Escritt)
Astrazeneca (AZN)
